RZLT
Rezolute, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Rezolute has 4 disclosed suppliers and 0 disclosed customers in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−1.02%
vs ±44.2% implied · ×0.02
shaded = implied · ▲▼ = realized
SentenceFor example, in 2017 we in-licensed (i) a fully human monoclonal antibody from XOMA Corporation ("XOMA"), who was acquired by Ligand Pharmaceuticals Incorporated on July 14, 2026, as well as (ii) a plasma kallikrein inhibitor portfolio from ActiveSite Pharmaceuticals ("ActiveSite") and in consideration for such licenses, we will continue to incur milestone payments and royalties as we progress product candidates through development.
SentenceIn August 2017, we entered into a Development and License Agreement with ActiveSite (the "ActiveSite License Agreement") pursuant to which we acquired the rights to ActiveSite's Plasma Kallikrein Inhibitor program ("PKI Portfolio").
RZLT 10-Kaccession 0001104659-25-090848
SentenceAdditionally, upon the future commercialization of ersodetug, we will be required to pay royalties to Ligand based on the net sales of the related products, and milestone payments up to an additional $185.0 million if future net sales related to ersodetug exceed annual targets ranging from $100.0 million to $1.0 billion.
RZLT 10-Kaccession 0001104659-26-110420
SentenceIn December 2017, we entered into a license agreement (the "Ersodetug License Agreement") with XOMA through its wholly-owned subsidiary, XOMA (U.S.) LLC, pursuant to which XOMA granted an exclusive global license to develop and commercialize ersodetug for all indications.
RZLT 10-Kaccession 0001104659-26-110420
Rezolute, Inc.
3.96
Largest filed tie
—
—
Expected move
Inputsspot 3.95exp Nov 20ATM strike 5ATM straddle 1.20IV 64%